Floatz logo

PREFEST COMPONENT NORGESTIMATE

Contraception

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Contraception cohort.

Asset / SponsorPhaseRating
ETONOGESTREL
University of Sao Paulo
Phase 4BB
NORELGESTROMIN
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
D

Same molecule, other indications

PREFEST COMPONENT NORGESTIMATE is also rated in:

Ovary CystDormant
B
Indicative ·
57 / 100
View asset →
migraine disorderDormant
CC
Indicative ·
47 / 100
View asset →
Depressive Disorder, MajorDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →